# SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07697586/  
OnCo record `nct07697586` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SKB264+SKB118 in non-small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.

## Summary

SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07697586 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 206 participants planned, started 2026-08-07 and due to reach its primary completion in 2028-08. Interventions recorded: SKB264+SKB118.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07697586
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate Sacituzumab Tirumotecan (SKB264) in Combination With SKB118 for the Treatment of Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Enrolled: 206

## Sources

- ClinicalTrials.gov NCT07697586: https://clinicaltrials.gov/study/NCT07697586

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07697586.json